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As diabetes develops, we currently waste the first ∼10 years of the natural his-
tory. If we found prediabetes and early diabetes when they first presented and
treated them more effectively, we could prevent or delay the progression of
hyperglycemia and the development of complications. Evidence for this comes
from trials where lifestyle change and/or glucose-loweringmedications decreased
progression from prediabetes to diabetes. After withdrawal of these interven-
tions, there was no “catch-up”dcumulative development of diabetes in the pre-
viously treated groups remained less than in control subjects. Moreover,
achieving normal glucose levels even transiently during the trials was associated
with a substantial reduction in subsequent development of diabetes. These find-
ings indicate that we can change the natural history through routine screening to
find prediabetes and early diabetes, combined with management aimed to keep
glucose levels as close to normal as possible, without hypoglycemia. We should
also test the hypothesis with a randomized controlled trial.
Diabetes is the major cause of kidney failure, blindness, and nontraumatic leg
amputations in U.S. adults and a leading cause of stroke and heart disease (1).
Diabetes cost the U.S. $176 billion in direct costs in 2012, amounting to 11% of
U.S. health care dollars (2), and is a critical public health problem in other countries
as well (3). Moreover, National Health and Nutrition Examination Surveys (NHANES)
from 2003–2006 and 2007–2010 show that while there were slight improvements in
the percentage of U.S. adults with diagnosed diabetes who had A1C levels .9%
(75 mmol/mol) (decreasing from 13.0 to 12.6%) and those who had A1C levels,8%
(64 mmol/mol) (increasing from 78.0 to 79.1%), there was no improvement in those
with A1C ,7.0% (53 mmol/mol) (decreasing from 56.8 to 52.2%) (4). We believe it
does not have to be like this.
The ongoing “epidemic” of diabetes, which currently affects 11% of U.S. adults
and 27% of those over 65 (1), is mostly type 2 diabetes and largely reflects the
“success of society.”We are living longer, we eat too much, and we are inactive. Being
older, overweight, and sedentarymakes us resistant to insulin, and if our bodies cannot
make enough insulin to compensate, glucose levels rise (5).
The earliest stage of type 2 diabetes is prediabetes (impaired glucose tolerance [IGT]
and/or impaired fasting glucose [IFG]), where glucose levels are higher than normal but
not in the diabetes range (1). Prediabetes tends to progress to diabetes, and over time,
persistent hyperglycemia leads to the complications that are the major source of
morbidity, mortality, and cost (Fig. 1A). This natural history reflects underlying loss
of b-cell function (6,7), due in part to factors such as elevated glucose and lipid levels,
inflammation, amyloid, and oxidative and endoplasmic reticulum stress.
Unfortunately, we waste the first;10 years (8) of the natural historydwhen the
disorder is easiest to treat. There are 79 million Americans with prediabetes and
7million with early type 2 diabetes (1) who are largely unrecognized, because we do
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not screen to find these states of dysgly-
cemia. Moreover, when we do make the
diagnosis, we do not treat in a way that
lowers glucose levels to normal. Ameri-
can Diabetes Association (ADA) guide-
lines call for adjusting therapy when
A1C reaches 7.0% (53 mmol/mol) (9),
which corresponds to glucose levels that
average 154 mg/dL (10). And as adjust-
ments in therapy are frequently delayed
(11,12), many patients have glucose lev-
els that are well above normal. For exam-
ple, Nichols et al. (13) reported in 2007
that over half of Kaiser Permanente
Northwest (KPNW) patients who initiated
metformin-sulfonylurea combination
therapy attained but failed to maintain
A1C levels below 8.0% (64 mmol/mol),
and continued combination therapy for
an average of almost 3 years before in-
sulin was added, with glucose exposure
equivalent to 32 months of A1C levels of
9% (75 mmol/mol). Similarly, Khunti
et al. (14) reported in 2013 that in the
U.K. Clinical Practice Research Datalink
(CPRD) databasedrepresentative of the
U.K. general populationdpatients who
were using two oral glucose-lowering
drugs and had A1C levels of at least
8.0% (64 mmol/mol) had a median time
of over 6.9 years before further intensifi-
cation of therapy, with a mean A1C level
of 9.1% (76mmol/mol) when therapywas
finally intensified.
As a consequence, the disease tends
to progress, and patients need more
and more medications. Many patients
eventually come to need mealtime insu-
lin and other drugs that can cause
hypoglycemiaditself a potential cause
of acute cardiovascular events. Johnston
et al. (15) found ICD-9-CM coding for out-
patient hypoglycemic events in patients
with type 2 diabetes to be independently
associated with acute cardiovascular
events in a retrospective analysis of a
large health care claims database. Glu-
cose levels of 41 to 70 mg/dL (2.3 to 3.9
mmol/L) were associated with increased
mortality in the prospective Normoglyce-
mia in Intensive Care Evaluation–Survival
Using Glucose Algorithm Regulation
(NICE-SUGAR) study (16). As NICE-SUGAR
involved intensive care unit inpatients,
the findings may not be generalizable
to outpatients. However, outpatients
with type 2 diabetes who are treated
with insulin and/or sulfonylureas ex-
hibit an increased frequency of asymp-
tomatic mild and severe hypoglycemia,
and severe hypoglycemia is associated
with increased ventricular ectopy (17,18).
Severe hypoglycemia is also indepen-
dently associated with QTc interval pro-
longation in both type 2 and type 1
diabetes (17,19), and there are plausible
biological mechanisms through which hy-
poglycemia could trigger acute cardiovas-
cular events (20,21).
But this natural history is not inevita-
ble. If we found prediabetes and early
diabetes when they first presented and
treated themmore effectively, we could
change the natural historydpreventing
or delaying the need for the use of meal-
time medications and other drugs that
can cause hypoglycemia, as well as the
development of complications. What is
the evidence that we could do this?
Patients with diabetes who are given
glucose-lowering medications earlier in
their natural historiesdwhen glucose
levels are lower and/or lower glucose
nadirs can be achieveddcan go longer
periods of time before another medica-
tion is needed. In another KPNW study
(22), half of the patients initiated on
metformin monotherapy who achieved
an A1C nadir of 7–8% (53–64mmol/mol)
were given another drug after 3 addi-
tional years, but half of those reaching a
nadir of 6–7% (42–53 mmol/mol) were
given another drug after 6.5 years, and
half of those achieving an A1C nadir of
less than 6% (42 mmol/mol) were given
another drug after 7.5 years. In the Treat-
ment Options for type 2 Diabetes in Ado-
lescents andYouth (TODAY) study (23,24),
diabetic youth were givenmetformin and
the end point was preserving A1C levels
below 8% (64 mmol/mol). Those who
failed or succeeded with treatment
were comparable in age, sex, and BMI.
However, those who failed were begun
on treatment when their A1C averaged
6.5% (48 mmol/mol), while those who
succeeded were begun when their A1C
averaged 5.7% (39 mmol/mol) and they
had correspondingly higher measures of
b-cell function. Such retrospective analy-
ses might be subject to length time bias,
but suggest the potential benefit of start-
ing treatment earlier.
Stronger evidence for early interven-
tion comes from randomized controlled
trials: the Da Qing IGT and Diabetes Study
in China (25), the Finnish Diabetes Pre-
vention Study (26), the U.S. Diabetes
Prevention Program (DPP) (27), and the
multinational Diabetes Reduction Assess-
ment With Ramipril and Rosiglitazone
Medication (DREAM) study (28). These
studies all showed that treatment with
lifestyle change or glucose-lowering
medications could reduce progression
from prediabetes to diabetes. On follow-
up after the studies ended and the in-
terventions were stopped or reduced,
additional study participants developed
diabetes. However, there was little
“catch-up”dthe cumulative development
of diabetes in the previously treated
Figure 1—Diagram illustrating the natural history of diabetes (progression from prediabetes to diabetes and development of diabetes complications
over time) without interventions (A); with interventions such as lifestyle change or a glucose-lowering medication that are successful in decreasing
progression from prediabetes to diabetes, but then are stopped (B); and with interventions that are titrated to keep glucose and A1C levels in the
normal range and are not stopped (C).
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groups remained less than that in the
untreated control groups (29–32). The
follow-up findings of the DREAM study
are shown in Fig. 2, and the pattern is
particularly clear with the DPP sub-
jects who had been randomized to the
troglitazone arm (which was stopped
after a little less than a year), as shown
in Fig. 3 (33). During 0.9 years of
treatment with troglitazone, the dia-
betes incidence rate was 3.0 cases/
100 person-years, considerably lower
than the rate of 12.0 cases/100 person-
years with placebo. However, during
the 3 years after troglitazone was
stopped, the diabetes incidence was
virtually identical to that of the placebo
groupdwithout evidence of “catch-up”
(Figs. 3 and 4).
These patterns are consistent with a
change in the natural histories of the
subjects in the treated groups (Fig.
1B). Moreover, in the Da Qing study,
follow-up 14 years after the trial ended
showed that the lifestyle change group
had a significant decrease in incident
severe diabetic retinopathy compared
with the control group (Fig. 5) (34);
after an additional 3 years of follow-
up, the lifestyle change group had de-
creases in cardiovascular and all-cause
mortality (35). These are clinical bene-
fits accompanying the glucose level
benefit.
In the DPP subject population,
achieving normal glucose levels ap-
peared to be particularly beneficial.
Among subjects who had not developed
diabetes at the end of the primary
study, those who achieved normal fast-
ing and 2-h oral glucose tolerance test
(OGTT) glucose levels at least once dur-
ing the average 3.2 years of the primary
study had a 56% decrease in develop-
ment of diabetes during follow-up after
the primary study ended (36). More-
over, it did not matter how normal glu-
cose was achieved, as the reduction
in the tendency to develop diabetes
was comparable among subjects in
the lifestyle change, metformin, and
control groups who achieved normal
glucose levels at least once. In addition,
the risk of subsequent development
of diabetes was decreased progres-
sively according to the number of
times normal glucose levels were
achieved; the risk reduction was 47,
61, and 67%when normal glucose levels
were achieved once, twice, or three
times, respectively. Attaining normal
glucose levels was predicted some-
what more strongly by better b-cell
function than by better insulin sensitiv-
ity, although both were statistically
significant.
HYPOTHESIS AND IMPLICATIONS
Thus, evidence supports a logical hypothe-
sis: In patients who are early in their natu-
ral histories and already have prediabetes,
1) identifying the problemat such an early
stage, and 2) keeping glucose levels nor-
mal or near-normal, will change the nat-
ural history of the diseasedpreventing or
delaying progression from prediabetes to
diabetes, and reducing the associated
development of diabetes complications.
What are the implications of this hy-
pothesis? Among DPP subjects, who at
baseline had a fasting glucose level 95–
125 mg/dL and a 2-h OGTT glucose level
140–199 mg/dL, 50% of subjects in the
placebo arm had developed diabetes af-
ter 8 years (and over 30% of the lifestyle
change group) (31). The hypothesis im-
plies that instead of half of untreated
DPP-typepatientswith prediabetes devel-
oping diabetes over 8 years and develop-
ing complications over another 10–20
years (depending on the level of diabetes
control), identifying those at high risk
early and keeping glucose levels normal
or near-normalwill extend the natural his-
tory. Patients with prediabetes should re-
main in a prediabetic state for a longer
period of timedand subsequent develop-
ment of complications should be reduced
(Fig. 1C). As prediabetes and early diabe-
tes are a continuum, there might be sim-
ilar benefits from identification and
intensive management of early diabetes.
As the natural history of diabetesdthe
tendency for the disease to getworse and
for complications to developdreflects
underlying loss of b-cell function, which
is due in part to glucotoxicity, treatment
that normalizes glucose levels should
Figure 2—Cumulative diabetes incidence in
the DREAM study, where subjects with pre-
diabetes were given rosiglitazone or pla-
cebo, including time points before and
after the primary study was stopped (verti-
cal dashed line). Adapted with permission
from Gerstein et al. (32).
Figure 3—Cumulative diabetes incidence in
the U.S. DPP study, showing subjects with
prediabetes who were given troglitazone or
placebo, including time points before and
after the primary study was stopped (verti-
cal dashed line). Adapted with permission
from Knowler et al. (33).
Figure 4—Cumulative diabetes incidence in
the U.S. DPP study, showing subjects with
prediabetes who were given troglitazone or
placebo, including only time points after the
primary study was stopped on 4 June 1988.
Adapted with permission from Knowler
et al. (33).
Figure 5—Cumulative incidence of severe di-
abetic retinopathy in theDaQing study, show-
ing subjects with prediabetes who were
randomized to receive instruction in diet 1
exercise or to be control subjects, including
time points before and after the primary study
was stopped (vertical dashed line). Adapted
with permission from Gong et al. (34).
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help preserve b-cell function. Evidence
for this is provided by several studies of
patients with newly diagnosed diabetes
showing that several weeks of intensive
insulin treatment (titrated to normalize
fasting and postprandial glucose levels)
improved b-cell function and was asso-
ciated with a high likelihood of being in
remission 1 year later (37–39). In the
study by Ryan et al. (38), patients were
given 2–3weeks of regular insulin before
meals and NPH at bedtime, with target
glucose levels,6 mmol/L before break-
fast and ,7 mmol/L 2 h after meals. Of
the 16 subjects in the study, 7 who
had mean baseline A1C levels of 12.3%
(111 mmol/mol) remained in remission
without pharmacologic therapy 1 year
later. In the study by Weng et al. (39),
patients given continuous subcutaneous
insulin infusions or multiple daily insulin
injections, titrated to achieve fasting
glucose,6.1 mmol/L and 2-h postpran-
dial glucose ,8.0 mmol/L and then
maintained for the following 2 weeks,
exhibited improved acute insulin re-
sponses to glucose, decreased ratios of
proinsulin to insulin levels, and remis-
sion rates of approximately 50% after
1 year. In these and other studies, the
initial benefit was less well sustained
when glucose normalization was achieved
with the aid of sulfonylureas; such a lack of
persistent benefits may reflect the ten-
dency of sulfonylureas to be associated
with “secondary failure” (40,41), possibly
by contributing to b-cell apoptosis (42).
Indirect evidence of preservation of
b-cell function is also provided by
the Outcome Reduction With Initial
Glargine Intervention (ORIGIN) study,
in which long-acting insulin was titrated
to keep fasting glucose levels in the nor-
mal range (at 95 mg/dL or less) (43). In
patients with prediabetes, treatment
with glargine insulin decreased progres-
sion to diabetes by about 30%. More-
over, in the combined treatment group
(diabetes 1 prediabetes), the amount
of insulin needed increased by only a
small amount over 4 yearsdfrom a me-
dian dosage of 0.31 units/kg at 1 year to
0.40 units/kg at 5 years, equivalent to a
rise in dosage from 28 to 36 units for a
subject weighing 200 pounds. Such titra-
tion resulted in very little deterioration
in A1C, with median levels of 6.4% at
baseline, 5.9% at 1 year, and 6.2% after
7 years (46, 41, and 42 mmol/mol, re-
spectively). Such relative stability of A1C
levels was qualitatively different from
the rise in A1C seen in the UK Prospec-
tive Diabetes Study (UKPDS) and in A
Diabetes Outcome Progression Trial
(ADOPT) (where glucose-lowering med-
ications were administered in a fixed
dosage, without titration) (41,44). In
ADOPT, mean A1C levels in the glyburide-
treated group were approximately 7.3%
at baseline, 6.4% at 3 months, and 7.6%
at 5 years (56, 46, and 60 mmol/mol,
respectively), although A1C levels rose
more slowly in the metformin and
rosiglitazone groups (approximately 7.3%
and 7.1% [56 and 54 mmol/mol, respec-
tively]); only the rosiglitazone group was
clearly still below baseline at 5 years.
Evidence of the potential benefit from
earlier identification of disease and initi-
ation of treatment comes from several
clinical trials. In the UKPDS, subjects pre-
senting with initial fasting glucose 140–
179 and $180 mg/dL appeared to be
recognized 3 and 5 years later in their
natural histories, respectively, than those
with fasting glucose ,140 mg/dL (45).
Earlier recognition was associated with
slightly lower blood pressure, but the
groups were comparable in age and lipid
levels, and they were all treated similarly.
However, subsequent development of mi-
crovascular diseasewas less in both earlier
recognition groups, and the group recog-
nized when initial fasting glucose was
,140 mg/dL also had reduced mortality.
Similar findings were obtained in sub-
groups in more recent trials. Intensive
treatment tended to reduce incident
cardiovascular disease (CVD) in subjects
in the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) study who
had baseline A1C levels #8.0% (64
mmol/mol) or who had not yet had a
CVD event (46). Intensive treatment
also tended to reduce incident CVD in
the Veterans Affairs Diabetes Trial
(VADT) in subjects who had little coro-
nary artery calcification at baseline (47)
and in those with shorter duration of
diagnosed diabetes, while it tended to
increase incident CVD in those with lon-
ger duration (48)dgenerally consistent
with the findings in the ACCORD study.
In the ORIGIN study, subjects who had a
baseline A1C $6.4% (46 mmol/mol)
and were assigned to glargine had a
median postrandomization change in
A1C of –0.65% (compared with –0.33%
in the standard care group) and a sig-
nificant decrease in a microvascu-
lar composite outcome of kidney and
eye disease (49)devidence of the po-
tential clinical benefit from keeping
glucose levels as close to normal as
possible.
HOW MEDICAL PRACTICE SHOULD
CHANGE
If the hypothesis is correct, thenmedical
practice should change in two ways
(Table 1).
First, screening to identify early dia-
betes and prediabetes should become
routine. The ADA guidelines currently
recommend screening with OGTTs or
measurement of fasting plasma glucose
or hemoglobin A1C (9). OGTTs are the
least convenient butmost sensitive (50),
while measurement of A1C is most con-
venient but least sensitive (51). As
Table 1—Changing the natural history of diabetesdhow medical practice should
change
1. Screening to identify early diabetes and prediabetes should become routine.
Oral glucose tolerance testsdmost sensitive, least convenient
Fasting plasma glucosedlowest cost, intermediate sensitivity and convenience
A1Cdmost convenient, least sensitive
2. Patients who are at high risk and have health prospects justifying improved glucose
control should have management aimed to keep glucose levels as close to normal as
possible without causing hypoglycemia.
Begin with lifestyle change
Include medications if appropriate
Begin with metformin for patients with diabetes
Consider metformin for patients with prediabetes if there is:
c IFG and
c IGT and
cAt least one risk factor for progression to diabetes (age,60 years, BMI$35 kg/m2,
a family history of diabetes, elevated triglycerides, reduced HDL cholesterol,
hypertension, or A1C .6.0% [42 mmol/mol])
Other medications that may be appropriate (DPP-4 inhibitors, SGLT-2 inhibitors,
GLP-1 analogs, a-glucosidase inhibitors, and possibly basal insulin and
thiazolidinediones)
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demonstrated in the Screening for Im-
paired Glucose Tolerance (SIGT) study, it
may also be possible to use two-step
screening, similar to screening for gesta-
tional diabetes mellitusdglucose mea-
surement 1 h after a 50-g oral glucose
challenge (at any time of day, without
a prior fast), followed, if abnormal, by a
75-g OGTT (52). Having every patient fill
out a brief diabetes risk questionnaire to
identify individualswho are at particularly
high risk might reduce the need for every
patient to have screening by measure-
ment of glucose levels. However, it may
be more practical to use near-universal
glucose screening, similar to what many
countries do to identify gestational diabe-
tes mellitus.
Second, patients who are at high risk
(53) and have health prospects justifying
improved glucose control (54,55) should
havemanagement aimed to keep glucose
levels as close to normal as possible
without causing hypoglycemia. Manage-
ment should begin with lifestyle change
and include medications if appropriate.
The ADA recommends use of metformin
for patients with diabetes and consider-
ation of metformin for patients with pre-
diabetes who have both 1) IFG and 2) IGT
and 3) at least one risk factor for pro-
gression to diabetes (age ,60 years,
BMI $35 kg/m2, a family history of di-
abetes, elevated triglycerides, reduced
HDL cholesterol, hypertension, or A1C
.6.0%) (56). The great majority of pa-
tients who have both IFG and IGT have
such risk factors, and a substantial per-
centage of patients with minimal IFG
(fasting plasma glucose 100–109 mg/dL)
also have IGT (57). Othermedications that
might be appropriate (in our opiniond
not necessarily supported in each instance
by clinical trial data) include dipeptidyl
peptidase-4 (DPP-4) inhibitors, sodium
glucose cotransporter 2 (SGLT-2) inhibi-
tors, GLP-1 analogs, and possibly basal
insulin and thiazolidinediones. Many
patients are likely to need such medi-
cations, as over 40% of the subjects in
the DPP lifestyle change group devel-
oped diabetes after 10 years of follow-
up (31). High-risk patients should also
have appropriate management of
other CVD risk factors.
Our recommendations may involve a
qualitative change in the approach to
management. Many practitioners may
currently use a “stepped care” strategy
(Table 2). With stepped care, patients
with prediabetes and early diabetes
would have management of cardiovas-
cular risk factors, use of aspirin (if appro-
priate), screening for eye and renal
complications, and education in medical
nutrition management. If lifestyle change
is insufficient to achieve glycemic goals,
pharmacologic therapy would be initi-
ated, usually with use of metformin as
recommended by the ADA and the Euro-
peanAssociation for the Study ofDiabetes
(EASD) guidelines (55,58). If metformin is
insufficient, another agent would then
be added. Many practitioners would
use a sulfonylurea as a second drug.
Although such agents carry a risk of hy-
poglycemia, they are available in inex-
pensive generic forms, there is wide
experience with their use, and they may
be more cost-effective than other, newer
drugs (59,60). Alternatives with less of a
risk of hypoglycemia include GLP-1 ana-
logs, DPP-4 inhibitors, thiazolidinediones,
SGLT-2 inhibitors, a-glucosidase inhibi-
tors, colesevelam, bromocriptine, and
glinides. If goals cannot be attained with
two or three such agents, insulin would
then be addeddeither as basal insulin
alone, basal plus mealtime insulin, or a
premixed insulin preparation. With the
stepped care strategy, insulin is typi-
cally added relatively late in the natural
history, and in practice, often when pa-
tients have had elevated A1C levels for a
substantial period of time (13,14). In
addition, with this strategy, use of
home glucose monitoring to guide man-
agement varies widely and may not be
initiated until patients are treated with
insulindagain, relatively late in the natu-
ral history.
In contrast, bringing glucose levels as
close to normal as possiblewhileminimiz-
ing the risk of hypoglycemia in patients
with prediabetes and early diabetes is
likely to require a qualitatively differ-
ent approachd“pattern care” (Table 3).
Pattern care management differs from
stepped care management in two major
ways: both glucose monitoring and basal
insulin may be needed relatively early in
the natural history.
A1C levels are strong predictors of the
development of both micro- and macro-
vascular disease (61,62), and it may be
possible in some patients to guide man-
agement with lifestyle change, metfor-
min, and addition of a second drug
largely on the basis of A1C levels. Keep-
ing A1C levels ,5.7% (39 mmol/mol)
(based on ADA guidelines [58]) would
provide assurance that in most patients,
glucose levels were unlikely to be in the
range of diabetes or prediabetes. Across
the NHANES and SIGT data sets, 60–70%
of subjects had normal glucose toler-
ance when A1C levels were ,5.7% (39
mmol/mol) (50); keeping A1C levels
,5.5% (37 mmol/mol) (based on the
Norfolk prospective study, where higher
levels were associated with increased
CVD, cancer, and all-cause mortality
Table 2—Stepped care strategy
c Insulin is typically added relatively late in the natural history.
c Use of home glucose monitoring to guide management varies and often is not initiated until patients are treated with insulindrelatively late in
the natural history.
1. All patients with prediabetes and early diabetes should havemanagement of cardiovascular risk factors, use of aspirin (if appropriate), screening
for eye and renal complications, and education in medical nutrition management.
2. If lifestyle change is insufficient to achieve glycemic goals, initiate pharmacologic therapy; usually begin with use of metformin as recommended
by ADA guidelines.
3. If metformin is insufficient, add another pharmacologic agent.
c Sulfonylureasdinexpensive and cost-effective, but carry a risk of hypoglycemia
c Alternatives with less risk of hypoglycemia (GLP-1 analogs, DPP-4 inhibitors, thiazolidinediones, SGLT-2 inhibitors, a-glucosidase inhibitors,
colesevelam, bromocriptine, and glinides)
4. If glycemic goals cannot be attained with two or three such agents, add insulindeither as basal insulin alone, basal plus mealtime insulin, or
a premixed insulin preparation.
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[63]) would provide greater assurance
that glucose levels would be normal.
GUIDING MANAGEMENT BY
GLUCOSE MONITORING
To the extent that the goal of manage-
ment is both to attain A1C goals and to
maintain glucose levels similar to those of
the DPP patientswho had normal glucose
levels when OGTTs were performed (36),
some home glucose monitoring will likely
be needed to determinewhether therapy
in individual patients needs to bedirected
toward fasting versus postprandial glu-
cose levels. Target glucose levels might
be similar to those that are normal by
ADA guidelines (58)dfasting glucose
,100 mg/dL and 2-h postprandial glu-
cose ,140 mg/dL. The normal range of
postprandial glucose levels is not well es-
tablished, but random plasma glucose
was measured 1.5–2.5 h after a meal in
705 subjects with normal OGTTs in the
SIGT study (52); only 3.7% had values
.130 mg/dL and only 2.1% had values
.140 mg/dL, suggesting that a 2-h post-
prandial glucose target of ,140 mg/dL is
reasonable. However, for most patients
who are early in their natural histories,
some monitoring of fasting glucose levels
along with measurement of A1C levels is
likely to be sufficient.
MANAGEMENT ACCORDING TO
GLUCOSE PATTERNS
With pattern management, fasting glu-
cose is best targeted with metformin
and, if needed, basal insulin given in
the evening. The use of insulin carries a
risk of hypoglycemia, but the ORIGIN
study showed that glargine insulin can
be used with little risk of hypoglycemia
in patients who are early in their natural
histories (43); there tends to be less hy-
poglycemia with use of either glargine or
detemir than with NPH, and the risk of
nocturnal hypoglycemia can be mini-
mized by giving detemir at bedtime and
glargine before supper. Although in the
ORIGIN study there was more hypoglyce-
mia with the use of glargine compared
with standard care (mostly metformin
and sulfonylureas), it is not clear whether
glargine was given before supper or
at bedtime, and A1C levels were also
0.2–0.3% higher in the standard care
group compared with the glargine group.
Detemir insulin has a different time
course of action (64) and reduced vari-
ability (65) compared with glargine insu-
lin, which can sometimes allow it to be
used successfully in place of glargine if
problems with hypoglycemia are encoun-
tered with glargine, although it has not
been used in a trial comparable to
ORIGIN. The new insulin degludec also
has less variability compared with glargine
insulin (66). As an alternative to basal in-
sulin, some patients may be able to
achieve target fasting glucose levels
by taking a small dose of glipizide (1.25–
5.0 mg) at bedtime, but the use of this
agent must be cautious because of the
risk of nocturnal hypoglycemia.
While most glucose-lowering drugs
reduce both fasting and postprandial
hyperglycemia, some tend to produce
greater absolute falls in postprandial
glucose levels. These include DPP-4 in-
hibitors, GLP-1 analogs, pioglitazone
(for which there has been extensive de-
scription of use early in the natural his-
tory), a-glucosidase inhibitors, and
SGLT-2 inhibitors, and as they act by dif-
ferent mechanisms, all of these can be
used in combination except DPP-4 inhib-
itors and GLP-1 analogs. If such drugs are
insufficient, many patients can attain
near-normal postprandial glucose levels
by further addition of a glinide before
meals. Only if such approaches fail would
use of short-acting insulin analogs be-
fore meals be recommended, due to the
increased risk of hypoglycemia with
such agents (67). In our opinion, it is dif-
ficult to achieve near-normal glucose
levels with the use of either mealtime in-
sulin, long-acting sulfonylureas, or pre-
mixed insulin, due to problems with
hypoglycemia.
Because of the complex underlying
pathophysiology responsible for the
metabolic abnormalities of type 2 diabe-
tes, combination therapy may be re-
quired very early. Fortunately, even in
the context of diabetes prevention,
low-dose combinations can provide
good efficacy with low rates of adverse
effects, as shown with rosiglitazone and
metformin (68). It is possible that path-
ophysiologic phenotyping aimed at re-
storing and preserving b-cell function
and identifying disease evolution in in-
dividuals will be useful beyond pattern
Table 3—Pattern care strategy
c Earlier use of home blood glucose monitoring to guide management
c Use of basal insulin earlier in the natural history
1. Home glucose monitoring and A1C measurements:
c Keeping A1C ,5.7% or ,5.5% (39 or 37 mmol/mol) may be sufficient if these goals can be met by management with lifestyle
change 1 metformin.
c In patients requiring additional medication treatment, some home glucose monitoring will likely be needed to determine whether therapy
in individual patients needs to be directed toward fasting vs. postprandial glucose levels.
c Target glucose levels: fasting ,100 mg/dL, 2-h postprandial ,140 mg/dL
c Early in the natural history, some monitoring of fasting glucose levels along with measurement of A1C levels is likely to be sufficient.
2. Management according to glucose patterns:
Fasting glucose ,100 mg/dL Postprandial glucose ,140 mg/dL
Metformin DPP-4 inhibitors
Basal insulin given in the evening GLP-1 analogs
c Glarginedbefore supper Pioglitazone
c Detemirdat bedtime SGLT-2 inhibitors
Glipizide (1.25–5.0 mg) at bedtime a-Glucosidase inhibitors
Glinides before meals
Short-acting insulin analogs before meals
3. It is difficult to achieve near-normal glucose levels with the use of either mealtime insulin, long-acting sulfonylureas, or premixed insulin, due to
problems with hypoglycemia.
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management (69,70). Individuals with
higher A1C levels may have them be-
cause of longer duration of disease
and/or more severe underlying patho-
physiology. In both the TODAY study
and the DPP, starting treatment when
A1C levels were lower (in TODAY) and/
or b-cell function was better (in both
TODAY and DPP) was associated with
improved outcomes (23,24,36). Alterna-
tively, DeFronzo et al. (71) have recom-
mended beginning management with
the combination of metformin, pioglita-
zone, and exenatide to provide “patho-
genic” targeting, but some patients may
require less and others more than this
combination to obtain normal glucose
levels. Further, it is possible that other
combinations may be as or possibly
even more effective.
There are potential concerns with
both the screening and the manage-
ment that we recommend. With respect
to population screening, the U.S. Pre-
ventive Services Task Force (USPSTF)
currently recommends screening only
for diabetes and only in patients with
sustained blood pressure (treated or un-
treated) greater than 135/80 mmHg
(72,73). While the USPSTF found “con-
vincing evidence that intensive glycemic
control in persons with clinically detected
(as opposed to screening-detected) dia-
betes can reduce progression of micro-
vascular disease,” it found “inadequate
evidence that early diabetes control as a
result of screening provides an incre-
mental benefit for microvascular clinical
outcomes compared with initiating
treatment after clinical diagnosis” (73).
However, the evidence that prompts our
recommendations is more recent than
the evidence upon which the USPSTF
recommendations were based (72), and
the clinical trial we outline below should
provide evidence that addresses the
USPSTF’s concern. The studies of long-
term outcomes in the Da Qing study
(34) and both short- and long-term out-
comes in the UKPDS (44,74) also provide
some reassurance that outcomes would
be positive in the study we propose, and
the ADA currently recommendsmore ex-
tensive screening (58).
Although population screening could
in theory lead to adverse effects such as
“false worry” about having abnormal test
results and “false reassurance” in those
with normal results (potentially leading
to less healthful behavior), the USPSTF
found little evidence that screening
causes short-term harms. Screening also
involves costs, but over 10 years, treat-
ment with lifestyle change or metformin
in the DPP was found to be cost-effective
or cost-saving, respectively (75). In addi-
tion, Chatterjee et al. (51) have also pro-
jected screening plus treatment to be
cost-effective or cost-saving, particularly
in high-risk groups (76). Additional cost-
effectiveness analyses will be needed to
help determine the extent to which the
expense of testing and monitoring, office
visits, and glucose-lowering medications,
used as we recommend, might be justi-
fied by potential savings from any reduc-
tions in the micro- and macrovascular
complications that account for the major
portion of diabetes-related health care
system expenditures (2).
Implementation of our management
recommendations by individual practi-
tioners and health care systems also
should be cautious in view of the find-
ings in the ACCORD study, which was
stopped early because intensification
of management in subjects with type 2
diabetes led to increased mortality (46).
However, the ACCORD subjects were
overall relatively late in their natural his-
tories (median duration of diabetes was
10 years) and many ACCORD subjects
already had CVD. In the ACCORD study,
the increase in mortality appeared to be
limited to those who were assigned to
intensive treatment but unable to achieve
A1C levels below 7.0% (53 mmol/mol)
(77), and increased mortality was not
found in subgroups who were earlier in
their natural histories (46). Moreover, in-
creased mortality was not found in the
ORIGIN study, where average duration
of diabetes was 5.5 years (43).
The hypothesis that such manage-
ment can change the natural history
also should be tested in a randomized
controlled trial. The trial could involve
high-risk subjects with baseline A1C
6.0–6.6% (42–49 mmol/mol) or higher,
who are all given support for change in
lifestyle. The control subjects might not
be given medications unless their A1C
reached 7.0–7.5% (53–58 mmol/mol),
(similar to the ongoing Glycemia Reduc-
tion Approaches in Diabetes: A Compar-
ative Effectiveness Study [GRADE] [78]),
whereas the treatment subjects would
be managed with medications titrated
to maintain glucose or A1C levels in
the normal range (e.g., A1C ,5.5%
[37mmol/mol], based on theNorfolk study
[63]), without hypoglycemia. The feasi-
bility of our recommended approaches
to glucose lowering will be partly ad-
dressed by the ongoing Restoring Insulin
Secretion (RISE) study (79) and A Study
to Compare Combination Regimen With
Vildagliptin and Metformin Versus Met-
formin in Treatment-na ı̈ve Patients
With Type 2 Diabetes Mellitus (VERIFY)
(80), and such management has been
used in the clinical practice of one of
the authors (L.S.P.) for the past several
years. A1C differences between the
groups would likely be sufficient to per-
mit evaluation of clinically significant
end points such as retinopathy and
microalbuminuria, as well as b-cell func-
tion. Inclusion of CVD as an end point
would require a larger, longer study.
Such a trial should be a high priority, as
positive findings would speed a change in
medical practice.
CONCLUSIONS
We believe we are at a time when we
can change the natural history of type 2
diabetes. Doing so should benefit the
health of millions of patients and might
also benefit health care systems, by re-
ducing resource use and costs (51,76).
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